The presented analysis based on five randomized trials including data of 717 patients with RAS/BRAF wild-type tumors represents a large and robust basis to evaluate the impact of exact primary tumor location in RAS/BRAF wild-type mCRC on clinical characteristics, prognosis and prediction of anti-EGFR antibody efficacy, when PTL is divided into six segments. Here, EGFR is linked to neoplasm.